European equities traded in the US as American depositary receipts were moving lower late Tuesday morning, declining 0.74% to 1,424.59 on the S&P Europe Select ADR Index. From continental Europe, the ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The ...

The Gonorrhea drugs in development market research report provides comprehensive information on the therapeutics under development for Gonorrhea, complete ...

Evaxion Biotech A/S has entered into an option and license agreement with MSD (Merck & Co. Inc.) for two preclinical vaccine candidates.

EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting ...

Danish clinical-stage AI-based vaccine developer Evaxion Biotech (Nasdaq: EVAX) has entered into an option and license ...

Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates.

Evaxion Biotech ( EVAX) shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its ...

Agreement provides MSD with options to license Evaxion's preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on Septem ...

根据协议条款，Evaxion授予MSD独家许可其疫苗候选物EVX-B2和EVX-B3的选择权。EVX-B2旨在预防淋病，而EVX-B3则针对一种未披露的传染因子。Evaxion将获得320万美元的预付款，如果MSD在2025年行使其许可选择权，Evaxion可能获得高达1000万美元。此外，Evaxion每种产品可能获得高达5.92亿美元的里程碑付款，外加净销售额的特许权使用费。

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...